Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.

Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, Wigley FM, Black CM, Fessler BJ, Merkel PA, Pope JE, Sweiss NJ, Doyle MK, Hellmich B, Medsger TA Jr, Morganti A, Kramer F, Korn JH, Seibold JR.

Ann Rheum Dis. 2011 Jan;70(1):32-8. doi: 10.1136/ard.2010.130658. Epub 2010 Aug 30.

2.

Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.

Khanna D, Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, Wigley FM, Moreland LW, Silver R, Kim YH, Steen VD, Firestein GS, Kavanaugh AF, Weisman M, Mayes MD, Collier D, Csuka ME, Simms R, Merkel PA, Medsger TA Jr, Sanders ME, Maranian P, Seibold JR; Relaxin Investigators and the Scleroderma Clinical Trials Consortium.

Arthritis Rheum. 2009 Apr;60(4):1102-11. doi: 10.1002/art.24380.

3.

Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial.

Merkel PA, Silliman NP, Denton CP, Furst DE, Khanna D, Emery P, Hsu VM, Streisand JB, Polisson RP, Akesson A, Coppock J, van den Hoogen F, Herrick A, Mayes MD, Veale D, Seibold JR, Black CM, Korn JH; CAT-192 Research Group; Scleroderma Clinical Trials Consortium.

Arthritis Rheum. 2008 May 15;59(5):699-705. doi: 10.1002/art.23564.

4.

Outcome measurements in scleroderma: results from a delphi exercise.

Gazi H, Pope JE, Clements P, Medsger TA, Martin RW, Merkel PA, Kahaleh B, Wollheim FA, Baron M, Csuka ME, Emery P, Belch JF, Hayat S, Lally EV, Korn JH, Czirjak L, Herrick A, Voskuyl AE, Bruehlmann P, Inanc M, Furst DE, Black C, Ellman MH, Moreland LW, Rothfield NF, Hsu V, Mayes M, McKown KM, Krieg T, Siebold JR.

J Rheumatol. 2007 Mar;34(3):501-9. Epub 2007 Feb 1.

PMID:
17299843
5.

Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.

Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, Coppock J, Hoogen Fv, Herrick A, Mayes MD, Veale D, Haas J, Ledbetter S, Korn JH, Black CM, Seibold JR; Cat-192 Study Group; Scleroderma Clinical Trials Consortium.

Arthritis Rheum. 2007 Jan;56(1):323-33.

6.

Durometry for the assessment of skin disease in systemic sclerosis.

Kissin EY, Schiller AM, Gelbard RB, Anderson JJ, Falanga V, Simms RW, Korn JH, Merkel PA.

Arthritis Rheum. 2006 Aug 15;55(4):603-9.

7.

Cartilage oligomeric matrix protein is overexpressed by scleroderma dermal fibroblasts.

Farina G, Lemaire R, Korn JH, Widom RL.

Matrix Biol. 2006 May;25(4):213-22. Epub 2006 Mar 7.

PMID:
16520029
9.

Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.

Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, Korn JH, Merkel PA, Rothfield N, Wigley FM, Moreland LW, Silver R, Steen VD, Weisman M, Mayes MD, Collier DH, Medsger TA Jr, Seibold JR; Relaxin Study Group; Scleroderma Clinical Trials Consortium.

J Rheumatol. 2005 May;32(5):832-40.

PMID:
15868618
10.

Scleroderma fibroblasts demonstrate enhanced activation of Akt (protein kinase B) in situ.

Jun JB, Kuechle M, Min J, Shim SC, Kim G, Montenegro V, Korn JH, Elkon KB.

J Invest Dermatol. 2005 Feb;124(2):298-303.

11.

Fibulin-2 and fibulin-5 alterations in tsk mice associated with disorganized hypodermal elastic fibers and skin tethering.

Lemaire R, Korn JH, Schiemann WP, Lafyatis R.

J Invest Dermatol. 2004 Dec;123(6):1063-9.

12.

Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick A, Merkel PA, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Black C.

Arthritis Rheum. 2004 Dec;50(12):3985-93.

13.

What's wrong with the scleroderma fibroblast?

Korn JH.

Clin Exp Rheumatol. 2004 Jan-Feb;22(3 Suppl 33):S64-5. No abstract available.

PMID:
15344600
14.

Global expression analysis of the fibroblast transcriptional response to TGFbeta.

Gardner H, Strehlow D, Bradley L, Widom R, Farina A, de Fougerolles A, Peyman J, Koteliansky V, Korn JH.

Clin Exp Rheumatol. 2004 Jan-Feb;22(3 Suppl 33):S47-57.

PMID:
15344598
15.

Mutant fibrillin 1 from tight skin mice increases extracellular matrix incorporation of microfibril-associated glycoprotein 2 and type I collagen.

Lemaire R, Farina G, Kissin E, Shipley JM, Bona C, Korn JH, Lafyatis R.

Arthritis Rheum. 2004 Mar;50(3):915-26.

16.

Scleroderma: a treatable disease.

Korn JH.

Cleve Clin J Med. 2003 Nov;70(11):954, 956, 958 passim.

PMID:
14650470
17.

Fibrosis in scleroderma.

Kissin EY, Korn JH.

Rheum Dis Clin North Am. 2003 May;29(2):351-69. Review.

PMID:
12841299
18.

The role of leukotrienes in alveolitis associated with scleroderma.

Simms RW, Korn JH.

Arthritis Rheum. 2003 Jun;48(6):1478-80. Review. No abstract available.

19.

Transforming growth factor beta induces fibroblast fibrillin-1 matrix formation.

Kissin EY, Lemaire R, Korn JH, Lafyatis R.

Arthritis Rheum. 2002 Nov;46(11):3000-9.

20.

Cytokine directed therapy in scleroderma: rationale, current status, and the future.

Simms RW, Korn JH.

Curr Opin Rheumatol. 2002 Nov;14(6):717-22. Review.

PMID:
12410097
21.

Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.

Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, Korn JH, Simms RW, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman MH, Collier DH, Weinstein A, Furst DE, Jiménez SA, White B, Seibold JR, Wigley FM; Scleroderma Clinical Trials Consortium.

Arthritis Rheum. 2002 Sep;46(9):2410-20.

22.

Apoptosis and myofibroblasts in the pathogenesis of systemic sclerosis.

Kissin E, Korn JH.

Curr Rheumatol Rep. 2002 Apr;4(2):129-35. Review.

PMID:
11890878
23.

The hcKrox gene family regulates multiple extracellular matrix genes.

Widom RL, Lee JY, Joseph C, Gordon-Froome I, Korn JH.

Matrix Biol. 2001 Nov;20(7):451-62.

PMID:
11691585
24.

Raynaud's phenomenon, scleroderma, overlap syndromes, and other fibrosing syndromes.

Korn JH.

Curr Opin Rheumatol. 2000 Nov;12(6):509-10. No abstract available.

PMID:
11092200
25.
26.

Fibroblast heterogeneity in physiological conditions and fibrotic disease.

Jelaska A, Strehlow D, Korn JH.

Springer Semin Immunopathol. 1999;21(4):385-95. Review.

PMID:
10945032
27.

Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial.

Seibold JR, Korn JH, Simms R, Clements PJ, Moreland LW, Mayes MD, Furst DE, Rothfield N, Steen V, Weisman M, Collier D, Wigley FM, Merkel PA, Csuka ME, Hsu V, Rocco S, Erikson M, Hannigan J, Harkonen WS, Sanders ME.

Ann Intern Med. 2000 Jun 6;132(11):871-9.

PMID:
10836913
28.

Can fibroblasts determine the late differing outcome between systemic sclerosis and primary hypertrophic osteoarthropathy (pachydermoperiostosis)?

Matucci-Cerinic M, Pignone A, Generini S, Korn JH.

Clin Exp Rheumatol. 2000 Jan-Feb;18(1):1-2. Review. No abstract available.

PMID:
10728436
29.

Induction of heme oxygenase-1 by hypoxia and free radicals in human dermal fibroblasts.

Panchenko MV, Farber HW, Korn JH.

Am J Physiol Cell Physiol. 2000 Jan;278(1):C92-C101.

30.

Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin).

Klings ES, Hill NS, Ieong MH, Simms RW, Korn JH, Farber HW.

Arthritis Rheum. 1999 Dec;42(12):2638-45.

31.

Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.

Farber HW, Graven KK, Kokolski G, Korn JH.

J Rheumatol. 1999 May;26(5):1195-6.

PMID:
10332990
32.

A potential role for protease nexin 1 overexpression in the pathogenesis of scleroderma.

Strehlow D, Jelaska A, Strehlow K, Korn JH.

J Clin Invest. 1999 Apr;103(8):1179-90.

33.

Biology of the scleroderma fibroblast.

Strehlow D, Korn JH.

Curr Opin Rheumatol. 1998 Nov;10(6):572-8. Review.

PMID:
9812218
34.
35.

Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.

Wigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman M, Martin R, Collier DH, Weinstein A, Furst DE, Jimenez SA, Mayes MD, Merkel PA, Gruber B, Kaufman L, Varga J, Bell P, Kern J, Marrott P, White B, Simms RW, Phillips AC, Seibold JR.

Arthritis Rheum. 1998 Apr;41(4):670-7.

PMID:
9550476
36.
37.

Cloning and characterization of hcKrox, a transcriptional regulator of extracellular matrix gene expression.

Widom RL, Culic I, Lee JY, Korn JH.

Gene. 1997 Oct 1;198(1-2):407-20.

PMID:
9370309
38.

Antipolymer antibodies, silicone breast implants, and fibromyalgia.

Korn JH.

Lancet. 1997 Apr 19;349(9059):1171. No abstract available.

PMID:
9113030
39.

Human mast cells activate fibroblasts: tryptase is a fibrogenic factor stimulating collagen messenger ribonucleic acid synthesis and fibroblast chemotaxis.

Gruber BL, Kew RR, Jelaska A, Marchese MJ, Garlick J, Ren S, Schwartz LB, Korn JH.

J Immunol. 1997 Mar 1;158(5):2310-7.

PMID:
9036979
40.

The rise and fall of deception in social psychology and personality research, 1921 to 1994.

Nicks SD, Korn JH, Mainieri T.

Ethics Behav. 1997;7(1):69-77.

PMID:
11654859
42.

Proceedings of the third international workshop on scleroderma research.

Black CM, Korn JH.

Matrix Biol. 1995 Dec;14(9):699-704. No abstract available.

PMID:
8785584
43.

Mast cells induce T-cell adhesion to human fibroblasts by regulating intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression.

Meng H, Marchese MJ, Garlick JA, Jelaska A, Korn JH, Gailit J, Clark RA, Gruber BL.

J Invest Dermatol. 1995 Dec;105(6):789-96.

44.

Aminopeptidase N: a constitutive cell-surface protein on human dermal fibroblasts.

Piela-Smith TH, Korn JH.

Cell Immunol. 1995 Apr 15;162(1):42-8.

PMID:
7704909
45.

Cross-linked elastin and collagen degradation products in the urine of patients with scleroderma.

Stone PJ, Korn JH, North H, Lally EV, Miller LC, Tucker LB, Strongwater S, Snider GL, Franzblau C.

Arthritis Rheum. 1995 Apr;38(4):517-24.

PMID:
7718005
46.

Diagnosis of arthritis by primary care providers versus rheumatologists: comment on the article by Chan et al.

Korn JH.

Arthritis Rheum. 1995 Mar;38(3):448-9. No abstract available.

PMID:
7880204
47.

Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis.

White B, Bauer EA, Goldsmith LA, Hochberg MC, Katz LM, Korn JH, Lachenbruch PA, LeRoy EC, Mitrane MP, Paulus HE, et al.

Arthritis Rheum. 1995 Mar;38(3):351-60.

PMID:
7880189
48.

The emergence of interest in the ethics of psychological research with humans.

McGaha AC, Korn JH.

Ethics Behav. 1995;5(2):147-59.

PMID:
11654198
49.

The immunopathogenesis of systemic sclerosis. Introduction.

Korn JH, LeRoy EC.

Int Rev Immunol. 1995;12(2-4):i-v. No abstract available.

PMID:
7650415
50.

Increased collagen synthesis in skin fibroblasts from patients with primary hypertrophic osteoarthropathy. Evidence for trans-activational regulation of collagen transcription.

Padula SJ, Broketa G, Sampieri A, Arakawa M, Matucci-Cerinic M, Downie E, Korn JH.

Arthritis Rheum. 1994 Sep;37(9):1386-94.

PMID:
7945504

Supplemental Content

Support Center